Baird Maintains Outperform on Inari Medical, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Baird analyst David Rescott has maintained an 'Outperform' rating on Inari Medical (NASDAQ:NARI) and raised the price target from $66 to $67.
October 29, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst David Rescott has maintained an 'Outperform' rating on Inari Medical and increased the price target from $66 to $67, indicating positive expectations for the stock.
The 'Outperform' rating suggests that the analyst expects Inari Medical to perform better than the market average. The increase in the price target from $66 to $67 indicates a positive outlook and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100